2028 年癌症生物标誌物市场预测——按癌症类型、产品类型、分析技术、应用、生物标誌物类型、服务和地区进行的全球分析

根据 Stratistics MRC 的数据，2022 年全球癌症生物标誌物市场规模将达到 147 亿美元，预计到 2028 年将达到 409.2 亿美元，预计将以 18.6% 的复合年增长率增长。

在肿瘤学中，生物标誌物是由肿瘤或某些身体反应分泌的物质，用于指示恶性肿瘤的存在。 使用多种基因组学和蛋白□□质组学技术，生物标誌物可以实现癌症的早期检测和快速、非侵入性诊断。 生物标誌物的应用包括预后预测、个性化医疗、药物研发和癌症诊断。

据美国国家癌症研究所估计，2018 年美国新诊断出 1,735,350 名癌症患者。 根据国际世界癌症研究基金会的数据，2018 年全球估计有 1800 万人受到影响。 肺癌和乳腺癌是全球最常报告的癌症，占 2018 年确诊病例总数的 12.3%。

市场动态

驱动程序

癌症患病率上升

癌症生物标誌物广泛用于个性化医疗、伴随诊断和其他疾病诊断，包括疾病风险评估和药物开发。 预计在预测期内推动癌症生物标誌物市场增长的主要因素之一是生物标誌物在疾病诊断中的使用越来越多。 全球癌症患病率上升正在增加对该疾病早期检测的需求，这反过来又推动了市场的扩张。 随着癌症生物标誌物在新兴国家和发达国家变得更加普遍，预计对癌症诊断和治疗的需求将会增加。

约束

治疗费用高

危害患者获得治疗和癌症治疗有效性的一个全球性问题是抗癌药物成本的上升。 药物的价格因国家而异。 在没有全民医疗保健的国家，患者必须支付医疗费用。 低收入和中等收入国家的大多数患者负担不起新的癌症治疗费用。 年轻患者、新移民、有色人种和没有私人医疗保险的人面临的风险最大。 基于价值的癌症治疗定价可以推动开发更好的药物并减少不必要的支出。

机会

存在潜在管道候选者

製药行业正在大力投资寻找可用于监测和识别癌症的新型生物标誌物。 一些候选人的开发週期即将结束。 预计这将显着提高市场增长率。 例如，隆德大学医院正在与南瑞典乳腺癌组织合作开展一项临床试验，比较阿托伐他汀的疗效和安全性。 创建用于癌症早期诊断的新生物标誌物应该是癌症生物标誌物领域的优势。 由于癌症生物标誌物相关商品和诊断试剂的扩张，预计市场将扩大。

威胁：

缺乏生物标誌物检测报销政策

儘管全球癌症患病率不断上升，需要诊断检测的患者数量不断增加，但新兴国家和发达国家缺乏生物标誌物检测报销政策，已成为限制全球生物标誌物需求的因素之一。 在新兴国家，癌症诊疗费用高昂也是限制市场增长的关键问题。 因此，接受生物标誌物检测的患者越来越少，越来越多的患者更喜欢其他更便宜的检测方法。

COVID-19 的影响：

由于在此期间研发活动中断，COVID-19 大流行对癌症生物标誌物市场产生了负面影响。 此外，SARS-CoV-2 感染还会产生难以解释的生物标誌物数据。 例如，根据内分泌学会 2020 年 9 月提供的信息，由于对急性病毒感染的强烈免疫反应具有潜在的混杂效应，因此很难解释对癌症的免疫反应指标。 此外，国家生物技术信息中心报告称，由于 COVID-19 大流行，英国的常规癌症筛查已被推迟。

预计在预测期内乳腺癌细分市场最大

据估计，乳腺癌领域的增长利润丰厚。 乳腺癌患病率的上升及其诊断意识的提高导致大量患者接受诊断测试。 影响乳腺癌领域发展的一个主要原因还包括越来越多的研究活动集中在用于乳腺癌检测的新生物标誌物上。

预计诊断部门在预测期内的复合年增长率最高。

癌症检测和治疗的进步已将重点从治癒疾病的近期目标转移到改善癌症倖存者（尤其是儿童癌症倖存者）的生活质量的长期目标。诊断领域有望增长在预测期内以最快的复合年增长率。 伴随诊断测试在癌症治疗中的普及有望推动市场增长。

市场份额最高的地区

由于癌症患者人数众多，预计亚太地区在预测期内将占据最大的市场份额。 提高公众对癌症早期检测必要性的认识是推动该地区市场增长的关键因素之一。 此外，该地区人口众多也有助于市场增长。

复合年增长率最高的地区：

预计欧洲在预测期内的复合年增长率最高。 正在鑑定对癌症风险评估和癌症早期检测很重要的生物标誌物。 生物标誌物，尤其是与遗传因素相关的生物标誌物，提供了一种定量方法来确定一个人何时更有可能患上癌症。 该地区市场扩张的驱动力是在各种恶性肿瘤患病率上升的背景下，对癌症诊断的需求不断增长。

主要发展：

2021 年 3 月，罗氏宣布 VENTANA ALK (D5F3) CDx 检测获得美国食品和药物管理局批准作为伴随诊断。 该试验是唯一获得 FDA 批准的 Lorbrena 伴随诊断，使具有这种癌症生物标誌物的患者能够被快速识别和更有效地治疗。

2020 年 11 月，安捷伦科技公司宣布启动“生物标誌物病理学家培训计划”，这是一项旨在帮助病理学家准确地对生物标誌物进行评分的全球性努力。做到了。 该计划最初在欧洲和北美以及中国和亚洲使用数字平台提供。

2020年7月，Thermo Fisher Scientific宣布与Chugai Pharmaceutical Co., Ltd.签订伴随诊断（CDx）协议，并已向厚生劳动省申请扩大使用Oncomin Dx日本目标测试 该协议的重点是在日本加速对 entrectinib 适应症的 NSCLC 患者进行当地生物标誌物测试。

这份报告提供了什么

• 区域和国家级细分市场的市场份额评估
• 向新进入者提出战略建议
• 2020、2021、2022、2025 和 2028 年的综合市场数据
• 市场趋势（驱动因素、制约因素、机会、威胁、挑战、投资机会、建议）
• 根据市场预测在关键业务领域提出战略建议
• 竞争格局映射关键共同趋势。
• 公司简介，包括详细的战略、财务状况和近期发展
• 映射最新技术进步的供应链趋势

免费定制优惠：

购买此报告的客户将获得以下免费定制选项之一：

• 公司简介
  • 其他市场参与者的综合概况（最多 3 家公司）
  • 主要参与者的 SWOT 分析（最多 3 家公司）
• 区域细分
  • 根据客户的要求对主要国家/地区的市场估计/预测/复合年增长率（注意：基于可行性检查）。
• 竞争基准
  • 根据产品组合、区域影响力和战略联盟对主要参与者进行基准测试

内容

第 1 章执行摘要

第二章前言

• 概览
• 利益相关者
• 调查范围
• 调查方法
  • 数据挖掘
  • 数据分析
  • 数据验证
  • 研究方法
• 调查来源
  • 主要研究来源
  • 二级研究来源
  • 假设

第三章市场趋势分析

• 司机
• 约束因素
• 机会
• 威胁
• 产品分析
• 技术分析
• 应用分析
• 新兴市场
• COVID-19 的影响

第 4 章波特五力分析

• 供应商的议价能力
• 买家的议价能力
• 替代品的威胁
• 新进入者的威胁
• 竞争公司之间的敌对关係

第 5 章全球癌症生物标誌物市场：按癌症类型分类

• 黑色素瘤
• 膀胱癌
• 乳腺癌
• 肾癌
• 前列腺癌
• 肺癌
• 非霍奇金淋巴瘤
• 结直肠癌
• 甲状腺癌
• 白血病
• 其他

第 6 章全球癌症生物标誌物市场：按产品分类

• 软件
• 消耗品
• 生长激素疗法
• 服务
• 其他

第 7 章全球癌症生物标誌物市场：按分析技术

• 免疫测定
• 组学技术
• 细胞遗传学
• 影像技术
• 生物信息学
• 其他

第 8 章全球癌症生物标誌物市场：按应用

• 预后
• 诊断
• 风险评估
• 研发
• 医院和专科诊所
• 製药和生物技术公司
• 其他用途

第 9 章全球癌症生物标誌物市场：按生物标誌物类型分类

• 遗传生物标誌物
• 蛋白质生物标誌物
• 安全
• 药效学
• 预后
• 代表
• 验证
• 功效
• 预测性
• 其他

第 10 章全球癌症生物标誌物市场：按服务分类

• 检测开发
• 样品製备
• 测试
• 生物标誌物
• 其他

第 11 章全球癌症生物标誌物市场：按地区

• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 意大利
  • 法国
  • 西班牙
  • 其他欧洲
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳大利亚
  • 新西兰
  • 韩国
  • 其他亚太地区
• 南美洲
  • 阿根廷
  • 巴西
  • 智利
  • 其他南美洲
• 中东和非洲
  • 沙特阿拉伯
  • 阿拉伯联合酋长国
  • 卡塔尔
  • 南非
  • 其他中东和非洲地区

第12章主要发展

• 合同、伙伴关係、协作和合资企业
• 收购与合併
• 新产品发布
• 业务扩展
• 其他关键策略

第13章公司简介

• Abbott Laboratories
• Myriad Genetics, Inc.
• F. Hoffmann-LA Roche Ltd.
• Asuragen, Inc.
• Biomerieux SA
• Seegene Technologies, INC.
• Thermo Fisher Scientific INC.
• R&d Systems, Inc.
• Becton Dickinson and Company
• Qiagen N.V.
• Hologic, Inc.
• Illumina, Inc.
• Bio-Rad Laboratories, INC.
• Agilent Technologies
• Merck Millipore

According to Stratistics MRC, the Global Cancer Biomarkers Market is accounted for $14.70 billion in 2022 and is expected to reach $40.92 billion by 2028 growing at a CAGR of 18.6% during the forecast period. In oncology, biomarkers are substances that a tumour or a particular human body reaction secretes to indicate the presence of malignancy. Using diverse genomes and proteomics methods, biomarkers enable early cancer detection and quick, noninvasive diagnosis of the disease. Applications for biomarkers include prognostics, personalised medicine, drug research and development, and cancer diagnosis.

According to, the National Cancer Institute, in 2018, an estimated 1,735,350 new cases of cancer was diagnosed in the United States. According to the World Cancer Research Fund International, an estimated 18.0 million people were suffering from globally in 2018. Lung and breast cancers were the most common cancers reported globally, contributing to 12.3% of the total number of the cases diagnosed in 2018.

Market Dynamics:

Driver:

Rising prevalence of cancer

Cancer biomarkers are widely utilised in personalised medicine, companion diagnostics, and other disease diagnostics, including risk assessment for disease and drug development. One of the primary factors anticipated to propel the growth of the cancer biomarkers market during the forecast period is the increasing utilisation of biomarkers in disease diagnosis. Globally increasing rates of cancer are driving up demand for early disease detection and, in turn, driving the market's expansion. The demand for cancer diagnostics and treatment is expected to raise as the prevalence of cancer biomarkers increases in both emerging and developed nations.

Restraint:

High treatment cost

An international issue that jeopardises patient access to care and the effectiveness of cancer therapy is the rising price of cancer medications. The cost of drugs varies widely between different countries. In nations without universal health coverage, patients must pay for their medical care. Most patients in low- and middle-income countries cannot afford novel cancer therapies. The most serious risks are to younger patients, new immigrants, people of colour, and those without private health insurance. Value-based oncology treatment pricing can promote the creation of better therapeutics and cut down on unnecessary spending.

Opportunity:

Presence of potential pipeline candidates

The pharmaceutical sector has made a large investment in the search for novel biomarkers that can be used to monitor and identify cancer. Several contenders' development cycles are coming to a close. This is expected to significantly increase market growth. For instance, Lund University Hospital is working with the South Sweden Breast Cancer Group to undertake clinical trials comparing the efficiency and safety of atorvastatin. The creation of new biomarkers for the early diagnosis of cancer should be advantageous for the oncology biomarker sector. Due to the growing availability of cancer biomarker-related goods and diagnostics, the market is anticipated to expand.

Threat:

Lack of reimbursement policies for biomarker testing

The lack of reimbursement policies for biomarker testing in emerging and developed nations is one of the factors that is restricting the demand for these biomarkers globally, despite the rising prevalence of cancer around the world and the growing number of patients needing diagnostic tests. The high cost of cancer diagnosis and treatment in developing nations is another significant issue limiting the market's growth. Due to this, fewer patients are having biomarker testing, and more patients are favouring other inexpensive detection methods.

COVID-19 Impact:

The COVID-19 pandemic had a negative impact on the cancer biomarkers market, owing to the interrupted research and development activities during this period. Additionally, the SARS-CoV-2 infection can produce biomarker data that are difficult to interpret. For instance, according to information supplied by the Society for Endocrinology in September 2020, indicators of the immunological response to cancer may be difficult to interpret due to the potential confounding effect of the strong immune response to acute viral infection. In addition, the U.K. delayed normal cancer screening as a result of the COVID-19 pandemic, according to a National Centre for Biotechnology Information report.

The breast cancer segment is expected to be the largest during the forecast period

The breast cancer segment is estimated to have a lucrative growth. A huge patient pool undergoing diagnostic testing is a result of the rising incidence of breast cancer and increased awareness of the diagnosis of the disease. Some of the key reasons influencing the growth of the breast cancer segment include this along with an increase in research activities concentrating on new biomarkers for breast cancer detection.

The diagnostics segment is expected to have the highest CAGR during the forecast period

The diagnostics segment is anticipated to witness the fastest CAGR growth during the forecast period, due to advancements in cancer detection and therapy, the emphasis has switched from immediate objectives like curing the disease to longer-term objectives like improving the quality of life for cancer survivors, particularly those with paediatric tumours. It is anticipated that the growing acceptance of companion diagnostic tests for cancer treatments will bolster market growth.

Region with highest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the high number of cancer cases in the region. Rising public awareness of the need of early cancer detection is one of the primary factors propelling the market's revenue growth in this area. Additionally, a significant population base in the area contributes to the market's revenue growth.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period. There has been the identification of a critical biomarker for estimating cancer risk and early cancer detection. A quantitative method to determine when someone is likely to develop cancer is provided by biomarkers, especially those linked to hereditary factors. The growing demand for cancer diagnostics, which is powered by the rising incidence rates of different malignancies, is what is driving market expansion in this region.

Key players in the market:

Some of the key players profiled in the Cancer Biomarkers Market include Abbott Laboratories, Myriad Genetics, Inc., F. Hoffmann-LA Roche Ltd., Asuragen, Inc., Biomerieux SA, Seegene Technologies, INC., Thermo Fisher Scientific INC., R&d Systems, Inc., Becton Dickinson and Company, Qiagen N.V., Hologic, Inc., Illumina, Inc., Bio-Rad Laboratories, INC., Agilent Technologies and Merck Millipore.

Key Developments:

In March 2021, Roche made an announcement that company has received the approval from US Food and Drug Administration for VENTANA ALK (D5F3) CDx Assay as a companion diagnostic. This assay test is the only test which was approved by FDA for as a companion diagnostic for LORBRENA and will help in identifying patients with this cancer biomarker quickly so they can be given more effective treatment.

In November 2020, Agilent Technologies Inc. made an announcement of the launch of the Biomarker Pathologist Training Program which is a worldwide initiative built to enable pathologists to score biomarkers precisely. The program initially was available in Europe and North America, along with China and Asia which utilizes a digital platform.

In July 2020, Thermo Fisher Scientific has announced that the company has signed a companion diagnostic (CDx) agreement with Chugai Pharmaceutical Co., Ltd., and has applied to the Ministry of Health, Labour and Welfare (MHLW) to increase the use of the Oncomine Dx Target Test in Japan. This agreement focuses on accelerating the local biomarker testing of NSCLC patients eligible for entrectinib in Japan.

Cancer Types Covered:

• Melanoma
• Bladder Cancer
• Breast Cancer
• Kidney Cancer
• Prostate Cancer
• Lung Cancer
• Non-Hodgkin's Lymphoma
• Colorectal Cancer
• Thyroid Cancer
• Leukemia
• Other Cancer Types

Products Covered:

• Software
• Consumables
• Growth Hormone Therapy
• Services
• Other Products

Profiling Technologies Covered:

• Immunoassay
• Omics Technologies
• Cytogenetics
• Imaging Technologies
• Bioinformatics
• Other Profiling Technologies

Applications Covered:

• Prognostics
• Diagnostics
• Risk Assessment
• Research & Development
• Hospitals & Specialty Clinics
• Pharmaceutical & Biotechnology Companies
• Other Applications

Biomarkers Types Covered:

• Genetic Biomarkers
• Protein Biomarkers
• Safety
• Pharmacodynamics
• Prognostic
• Surrogate
• Validation
• Efficacy
• Predictive
• Other Biomarker Types

Services Covered:

• Assay Development
• Sample Preparation
• Testing
• Biomarkers
• Other Services

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Technology Analysis
• 3.8 Application Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Cancer Biomarkers Market, By Cancer Type

• 5.1 Introduction
• 5.2 Melanoma
• 5.3 Bladder Cancer
• 5.4 Breast Cancer
• 5.5 Kidney Cancer
• 5.6 Prostate Cancer
• 5.7 Lung Cancer
• 5.8 Non-Hodgkin's Lymphoma
• 5.9 Colorectal Cancer
• 5.10 Thyroid Cancer
• 5.11 Leukemia
• 5.12 Other Cancer Types

6 Global Cancer Biomarkers Market, By Product

• 6.1 Introduction
• 6.2 Software
• 6.3 Consumables
• 6.4 Growth Hormone Therapy
• 6.5 Services
• 6.6 Other Products

7 Global Cancer Biomarkers Market, By Profiling Technologies

• 7.1 Introduction
• 7.2 Immunoassay
• 7.3 Omics Technologies
• 7.4 Cytogenetics
• 7.5 Imaging Technologies
• 7.6 Bioinformatics
• 7.7 Other Profiling Technologies

8 Global Cancer Biomarkers Market, By Application

• 8.1 Introduction
• 8.2 Prognostics
• 8.3 Diagnostics
• 8.4 Risk Assessment
• 8.5 Research & Development
• 8.6 Hospitals & Specialty Clinics
• 8.7 Pharmaceutical & Biotechnology Companies
• 8.8 Other Applications

9 Global Cancer Biomarkers Market, By Biomarkers Type

• 9.1 Introduction
• 9.2 Genetic Biomarkers
• 9.3 Protein Biomarkers
• 9.4 Safety
• 9.5 Pharmacodynamics
• 9.6 Prognostic
• 9.7 Surrogate
• 9.8 Validation
• 9.9 Efficacy
• 9.10 Predictive
• 9.11 Other Biomarker Types

10 Global Cancer Biomarkers Market, By Service

• 10.1 Introduction
• 10.2 Assay Development
• 10.3 Sample Preparation
• 10.4 Testing
• 10.5 Biomarkers
• 10.6 Other Services

11 Global Cancer Biomarkers Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 Abbott Laboratories
• 13.2 Myriad Genetics, Inc.
• 13.3 F. Hoffmann-LA Roche Ltd.
• 13.4 Asuragen, Inc.
• 13.5 Biomerieux SA
• 13.6 Seegene Technologies, INC.
• 13.7 Thermo Fisher Scientific INC.
• 13.8 R&d Systems, Inc.
• 13.9 Becton Dickinson and Company
• 13.10 Qiagen N.V.
• 13.11 Hologic, Inc.
• 13.12 Illumina, Inc.
• 13.13 Bio-Rad Laboratories, INC.
• 13.14 Agilent Technologies
• 13.15 Merck Millipore

List of Tables

• Table 1 Global Cancer Biomarkers Market Outlook, By Region (2020-2028) ($MN)
• Table 2 Global Cancer Biomarkers Market Outlook, By Cancer Type (2020-2028) ($MN)
• Table 3 Global Cancer Biomarkers Market Outlook, By Melanoma (2020-2028) ($MN)
• Table 4 Global Cancer Biomarkers Market Outlook, By Bladder Cancer (2020-2028) ($MN)
• Table 5 Global Cancer Biomarkers Market Outlook, By Breast Cancer (2020-2028) ($MN)
• Table 6 Global Cancer Biomarkers Market Outlook, By Kidney Cancer (2020-2028) ($MN)
• Table 7 Global Cancer Biomarkers Market Outlook, By Prostate Cancer (2020-2028) ($MN)
• Table 8 Global Cancer Biomarkers Market Outlook, By Lung Cancer (2020-2028) ($MN)
• Table 9 Global Cancer Biomarkers Market Outlook, By Non-Hodgkin's Lymphoma (2020-2028) ($MN)
• Table 10 Global Cancer Biomarkers Market Outlook, By Colorectal Cancer (2020-2028) ($MN)
• Table 11 Global Cancer Biomarkers Market Outlook, By Thyroid Cancer (2020-2028) ($MN)
• Table 12 Global Cancer Biomarkers Market Outlook, By Leukemia (2020-2028) ($MN)
• Table 13 Global Cancer Biomarkers Market Outlook, By Other Cancer Types (2020-2028) ($MN)
• Table 14 Global Cancer Biomarkers Market Outlook, By Product (2020-2028) ($MN)
• Table 15 Global Cancer Biomarkers Market Outlook, By Software (2020-2028) ($MN)
• Table 16 Global Cancer Biomarkers Market Outlook, By Consumables (2020-2028) ($MN)
• Table 17 Global Cancer Biomarkers Market Outlook, By Growth Hormone Therapy (2020-2028) ($MN)
• Table 18 Global Cancer Biomarkers Market Outlook, By Services (2020-2028) ($MN)
• Table 19 Global Cancer Biomarkers Market Outlook, By Other Products (2020-2028) ($MN)
• Table 20 Global Cancer Biomarkers Market Outlook, By Profiling Technologies (2020-2028) ($MN)
• Table 21 Global Cancer Biomarkers Market Outlook, By Immunoassay (2020-2028) ($MN)
• Table 22 Global Cancer Biomarkers Market Outlook, By Omics Technologies (2020-2028) ($MN)
• Table 23 Global Cancer Biomarkers Market Outlook, By Cytogenetics (2020-2028) ($MN)
• Table 24 Global Cancer Biomarkers Market Outlook, By Imaging Technologies (2020-2028) ($MN)
• Table 25 Global Cancer Biomarkers Market Outlook, By Bioinformatics (2020-2028) ($MN)
• Table 26 Global Cancer Biomarkers Market Outlook, By Other Profiling Technologies (2020-2028) ($MN)
• Table 27 Global Cancer Biomarkers Market Outlook, By Application (2020-2028) ($MN)
• Table 28 Global Cancer Biomarkers Market Outlook, By Prognostics (2020-2028) ($MN)
• Table 29 Global Cancer Biomarkers Market Outlook, By Diagnostics (2020-2028) ($MN)
• Table 30 Global Cancer Biomarkers Market Outlook, By Risk Assessment (2020-2028) ($MN)
• Table 31 Global Cancer Biomarkers Market Outlook, By Research & Development (2020-2028) ($MN)
• Table 32 Global Cancer Biomarkers Market Outlook, By Hospitals & Specialty Clinics (2020-2028) ($MN)
• Table 33 Global Cancer Biomarkers Market Outlook, By Pharmaceutical & Biotechnology Companies (2020-2028) ($MN)
• Table 34 Global Cancer Biomarkers Market Outlook, By Other Applications (2020-2028) ($MN)
• Table 35 Global Cancer Biomarkers Market Outlook, By Biomarkers Type (2020-2028) ($MN)
• Table 36 Global Cancer Biomarkers Market Outlook, By Genetic Biomarkers (2020-2028) ($MN)
• Table 37 Global Cancer Biomarkers Market Outlook, By Protein Biomarkers (2020-2028) ($MN)
• Table 38 Global Cancer Biomarkers Market Outlook, By Safety (2020-2028) ($MN)
• Table 39 Global Cancer Biomarkers Market Outlook, By Pharmacodynamics (2020-2028) ($MN)
• Table 40 Global Cancer Biomarkers Market Outlook, By Prognostic (2020-2028) ($MN)
• Table 41 Global Cancer Biomarkers Market Outlook, By Surrogate (2020-2028) ($MN)
• Table 42 Global Cancer Biomarkers Market Outlook, By Validation (2020-2028) ($MN)
• Table 43 Global Cancer Biomarkers Market Outlook, By Efficacy (2020-2028) ($MN)
• Table 44 Global Cancer Biomarkers Market Outlook, By Predictive (2020-2028) ($MN)
• Table 45 Global Cancer Biomarkers Market Outlook, By Other Biomarker Types (2020-2028) ($MN)
• Table 46 Global Cancer Biomarkers Market Outlook, By Service (2020-2028) ($MN)
• Table 47 Global Cancer Biomarkers Market Outlook, By Assay Development (2020-2028) ($MN)
• Table 48 Global Cancer Biomarkers Market Outlook, By Sample Preparation (2020-2028) ($MN)
• Table 49 Global Cancer Biomarkers Market Outlook, By Testing (2020-2028) ($MN)
• Table 50 Global Cancer Biomarkers Market Outlook, By Biomarkers (2020-2028) ($MN)
• Table 51 Global Cancer Biomarkers Market Outlook, By Other Services (2020-2028) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.